Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on May 6, 2022. The report addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with Nasdaq listing standards rather than financial performance metrics.
Material Changes and Listing Status
- Market Value Deficiency: On May 6, 2022, the company received notice from Nasdaq that it failed to meet the Market Value of Listed Securities (MVLS) requirement under Rule 5450(b)(2)(A), which mandates a minimum market value of $50.0 million.
- Compliance Timeline: The company has 180 calendar days (until November 2, 2022) to regain compliance. Compliance is achieved if the requirement is met for 10 consecutive business days.
- Current Listing Status: The notice does not immediately impact the listing of the company's common stock on The Nasdaq Global Market.
- Prior Deficiency: The company previously received notice on December 3, 2021, regarding a failure to maintain the minimum average closing price of $1.00 per share required for the Nasdaq Global Select Market.
Outlook, Risks, and Management Commentary
Management intends to monitor the market value of its common stock and evaluate options to regain compliance. Potential actions include transferring the listing to The Nasdaq Capital Market. The filing explicitly states there can be no assurance that the company will regain compliance, maintain other listing requirements, or successfully transfer its listing. Failure to comply by the November 2, 2022 deadline will result in a delisting notification, subject to appeal.
Investor Verification Checklist
- Verify the current market capitalization of AcelRx Pharmaceuticals, Inc. to assess the gap from the $50.0 million threshold.
- Monitor the stock's daily closing price to track progress toward the 10-day compliance window.
- Review subsequent filings for any announcements regarding a potential transfer to The Nasdaq Capital Market.
- Check for updates on the prior minimum bid price deficiency ($1.00) mentioned in the December 2021 notice.